Hong Kong, China – December 4, 2025 - SeekIn Inc., a biotech company specializing in blood-based cancer early detection and monitoring technologies, announced two major advances in liquid biopsy at the 14th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS), held in Hong Kong on December 3–5, 2025. SeekIn presented a cost-effective “Two-Step” multi-cancer early detection strategy and clinical data on SeekInClarity®, its pan-cancer/pan-indication non-invasive treatment response monitoring test.
During the oral presentation session, Dr. Mao Mao, Founder & CEO of SeekIn Inc., introduced the innovative Two-Step strategy for multi-cancer early detection, which was validated in a prospective real-world cohort. In this approach, individuals are first screened using the cost-efficient OncoSeek® test, and those with positive results then undergo confirmatory testing with SeekInCare®. In a cohort of 1,203 participants (10 cancer patients and 1,193 non-cancer individuals), the Two-Step strategy reduced the false positive rate from 16.2% to 1.8% compared with using OncoSeek alone, achieving a specificity of 98.2%. A simulation of population-wide screening in 5 million people demonstrated that, compared with an established multi-cancer early detection test (Galleri), the total screening cost was reduced by 4.9-fold and the cost per cancer patient detected was reduced by 6.8-fold.
In a separate poster presentation, SeekIn highlighted SeekInClarity, a pan-cancer/pan-indication non-invasive treatment response monitoring test that integrates copy number alterations and fragment size patterns of cell-free DNA with protein tumor biomarkers, supported by big data analytics and artificial intelligence. The test generates a Molecular Tumor Burden (MTB) score to evaluate therapeutic efficacy dynamically. In a prospective study of 116 lymphoma patients, SeekInClarity demonstrated strong prognostic value: patients who remained test-positive after two cycles of therapy had significantly shorter progression-free and overall survival compared with those who converted to negative. Notably, among 108 patients assessed as “responders” by interim PET/CT, SeekInClarity identified an additional 24 patients with persistent MTB positive status, who showed a markedly higher risk of disease progression.
Both the Two-Step screening strategy and SeekInClarity are based on liquid biopsy, offering non-invasive, convenient, and cost-effective solutions for cancer screening and monitoring. By substantially reducing false positives, lowering overall screening costs, and enabling earlier detection of treatment failure than conventional imaging, these technologies are designed to make precision oncology more accessible and practical at scale.
“From optimizing the screening pathway with our Two-Step strategy to enabling earlier, more precise treatment monitoring with SeekInClarity, SeekIn is committed to driving a shift toward earlier, more accurate, and more affordable cancer management,” said Dr. Mao. “We aim to translate cutting-edge multi-omics and AI technologies into broadly accessible clinical solutions that can benefit patients worldwide.”
CNAPS is a leading international forum in the field of circulating nucleic acids, bringing together scientists, clinicians, and industry partners to discuss advances in biology, analytical technologies, and clinical applications across oncology, prenatal diagnostics, transplantation, and other areas. SeekIn’s presentations at CNAPS 2025 underscore the company’s strong technological foundation and vision for transforming cancer screening and management through liquid biopsy-based multi-omics and AI innovations.